CANOPY GROWTH CORPORATION
Canopy Growth Corporation (CGC) is a Canadian cannabis producer active in adult‑use and medical markets, with branded products that include flower, oils, edibles and beverages. With a market capitalisation of US$645.37M, the company has shifted focus towards operational efficiency and portfolio rationalisation after several years of heavy investment and restructuring. Key considerations for investors are its exposure to regulatory change (particularly any US federal legalisation), competitive pressure from other licensed producers and consumer packaged goods companies, and ongoing challenges returning to sustained profitability. Liquidity, balance‑sheet strength and execution on cost savings are material variables to monitor. This summary is general educational information and not personal advice; cannabis stocks can be volatile and values may rise or fall. Investors should assess suitability relative to their objectives, risk tolerance and time horizon, and consider seeking regulated financial advice before acting.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Canopy Growth's stock with a target price of $4.8, indicating potential for growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
BRIDGEBIO PHARMA INC
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
Baskets Featuring CGC
Canada Domestic Champions Explained | Trade War Shield
Recent U.S. tariffs have caused a contraction in Canada's export-driven economy, creating a unique investment opportunity. This theme focuses on Canadian companies that serve the domestic market and are insulated from international trade disputes.
Published: August 30, 2025
Explore BasketVice Arbitrage
Get exposure to companies leading the transformation of once-prohibited activities into booming legal industries. These carefully selected stocks represent market leaders capitalizing on shifting regulations in sports betting, cannabis, and more, unlocking tremendous growth potential.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Market recovery watch
Watch for signs of revenue stabilisation and margin improvement as indicators of recovery, though performance can vary and is not guaranteed.
Product innovation
New formats and branded products can drive consumer demand, but success depends on execution, distribution and changing consumer tastes.
Regulatory drivers
Shifts in regulation, especially in the US, could materially change the opportunity set, but regulatory outcomes are uncertain and carry risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
